Japan Paves Way For Pfizer/Wyeth's Viviant To Hit Crowded Osteo Space
This article was originally published in PharmAsia News
Executive Summary
The First Subcommittee on New Drugs at Japan's Ministry of Health June 3 recommended six drugs for approval, including Wyeth/Pfizer's Viviant (bazedoxifene), clearing a hurdle for the merged companies' lead selective estrogen reuptake modulator for postmenopausal osteoporosis in Japan's crowded market